Mode
Text Size
Log in / Sign up
Phase 3 N=398 Randomized Treatment

Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers

Smoking · Pulmonary Disease, Chronic Obstructive · Tobacco Use Disorder

Enrolled (actual)
398
Serious AEs
4.3%
Results posted
Jul 2017
Primary outcome: Primary: Smoking Abstinence (Point Prevalent) — 23; 24 Participants — p=0.88

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Standard Smoking Cessation (Other); Extended Nicotine Replacement Therapy (Other); Nicotine replacement therapy (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Kansas Medical Center
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Smoking Abstinence (Point Prevalent)
23; 24 0.88
SECONDARY
Sustained Abstinence
15; 12 0.55
SECONDARY
Quit Attempts
4.6; 3.7; 4.5; 4.8; 5.7; 6.2 0.40
SECONDARY
Average Cigarettes Per Day
7.9; 10.5; 8.1; 9.1; 8.5; 8.1 0.05
SECONDARY
Carbon Monoxide Exposure
15.0; 17.4; 14.6; 15.4; 15.5; 13.8 0.05
SECONDARY
Carcinogen Exposure
279.0; 320.1; 178.2; 186.0; 190.4; 183.5 0.39
SECONDARY
Respiratory Function
55.4; 56.8 0.42
SECONDARY
Respiratory Symptoms
17.8; 19.3; 17.9; 18.1; 17.5; 18.2 0.27
SECONDARY
Respiratory-related Hospital Visits
176; 169; 11; 15; 2; 7 0.06
SECONDARY
Cardiac-related Hospital Visits
181; 185; 7; 6; 1; 0
SECONDARY
7-day Abstinence
27; 16; 25; 14; 28; 20 0.08
SECONDARY
Cotinine
2652.5; 3378.1; 2390.7; 3342.3; 2159.0; 2363.7 0.0149 sig
SECONDARY
Average Cigarettes Per Day (Continued Smokers Only)
8.7; 11.4; 9.1; 9.9; 9.7; 9.3 0.05
SECONDARY
Carbon Monoxide Exposure (Continued Smokers Only)
16.4; 18.8; 16.0; 17.0; 17.4; 15.8 0.08
SECONDARY
Carcinogen Exposure (Continued Smokers Only)
314.6; 337.6; 219.8; 217.1; 257.0; 247.5 0.77
SECONDARY
Cotinine (Continued Smokers Only)
2771.2; 3305.8; 2850.7; 3502.2; 2733.9; 2782.7 0.0918

Summary

Long-term NRT has not been studied in patients with COPD, and smokers in the United States with COPD are still asked to choose between immediate quitting or continued smoking. The purpose of this study is to see if guided maintenance therapy (GMT), using long-term NRT, might prove to be a reasonable alternative to the standard approach of asking patients to quit immediately. The investigators believe that GMT with long-term NRT will reduce overall exposure to cigarette smoke, reduce harm related to smoking, and ultimately lead to greater quit rates. In this study, 398 smokers with COPD will be randomly assigned to either receive: 1) traditional smoking cessation (SC) or 2) long-term, guided maintenance therapy with NRT (GMT). The SC intervention will be based on a standard approach to smoking cessation, including smoking cessation counseling supplemented with combination NRT (a nicotine patch plus the patient's choice of gum or lozenge) if they are willing to make a quit attempt. The GMT intervention will consist of counseling, focused on medication adherence and smoking reduction, plus 52 weeks of combination NRT. After 3, 6 and 12 months of treatment, we will compare the two treatments based on their effects on smoking cessation, number of cigarettes smoked, exposure to carbon monoxide and smoking-related carcinogens, COPD symptoms, breathing function, and smoking-related hospitalizations or death. The investigators will also analyze the data in such a way that will be able to identify which patients are most likely to benefit from treatment. This analysis will allow patients to estimate their chances of success based on their own personal characteristics and which treatment they choose. The investigators study addresses research priorities identified in recent smoking cessation guidelines and builds upon the input of our Patient Advisory Panel and our Stakeholder Advisory Committee. This study reflects the interests expressed by smokers in prior surveys and addresses the limited reach and effectiveness of traditional approaches to smoking cessation. If our GMT approach is effective, our study could change the recommendations provided in clinical practice guidelines and change the way that insurance companies pay for smoking cessation treatment. GMT could provide an alternative for millions of smokers with COPD who are not currently benefiting from traditional approaches to smoking cessation

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Physician-diagnosed COPD
  • Smoke 5 or more cigarettes/day
  • Smoke cigarettes on 25 or more of the last 30 days
  • Speak either English or Spanish
  • Willing to take nicotine replacement therapy for up to 1 year and participate in study procedures

Exclusion Criteria

  • Reside in a facility that does not allow smoking
  • Don't have an address and telephone
  • Unstable cardiac condition (e.g. unstable angina or myocardial infarction in the past 30 days)
  • Pregnant or breastfeeding
  • Terminal illness with less than 12 month life expectancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02148445). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search